Resources
274 Results (showing 1 - 10)
Results sorted by updated date (newest first)
Results sorted by updated date (newest first)
Posted 2/14/2023 (updated 4/15/2024)
The RCORP Data Coordinator meeting series began in July 2022, hosted by RCORP-Evaluation in partnership with RCORP-TA. These meetings provide an opportunity for the JBS RCORP team to work with Data Coordinators and other consortium staff to address topics impacting data quality, reporting and utilization. Discussion in these meetings helps to inform additional webinar sessions and resources, developed to meet grantee needs.
Posted 5/26/2021 (updated 4/10/2024)
Posted 5/26/2021 (updated 4/10/2024)
Posted 5/26/2021 (updated 4/10/2024)
Posted 5/26/2021 (updated 4/10/2024)
What is the importance of responsive leadership? The complex choices facing leaders at every level of an organization require inclusive assessments and innovative solutions. Leaders face questions about who should be sitting around the table and which two or three responses might work to address a community consortium challenge. The presenter will review interventions for engaging in complex situations and a new normal.
Posted 5/26/2021 (updated 4/10/2024)
Presenters will review resources available to rural grantees through their respective organizations.
Posted 5/3/2021 (updated 4/10/2024)
The U.S. Food and Drug Administration (FDA) announced on April 30, 2021 the approval of a higher dose naloxone hydrochloride nasal spray product to treat opioid overdose. The newly approved product delivers 8 milligrams (mg) of naloxone into the nasal cavity. The FDA had previously approved 2 mg and 4 mg naloxone nasal spray products.
Naloxone is a medicine that can be administered by individuals with or without medical training to help reduce opioid overdose deaths. If naloxone is administered quickly, it can counter the opioid overdose effects, usually within minutes. A higher dose of naloxone provides an additional option in the treatment of opioid overdoses.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief defines psychostimulants; explains why psychostimulant use disorder is under-addressed, particularly in rural areas; reviews the reasons why people use psychostimulants and the harms they can cause; and addresses the impact of COVID-19 on psychostimulant use.
Posted 4/21/2021 (updated 4/5/2024)
This News Brief describes the need for harm reduction and treatment services in rural areas for people who use psychostimulants and how those services can be provided by the opioid treatment program
Posted 3/25/2021 (updated 4/5/2024)
Documentation, Coding, and Billing for SUD/OUD via Medication-Assisted Treatment (MAT): A Rural and Community Health Focus
The presenter will outline the steps needed to effectively document, code, and bill for services including screening for SUD/OUD and providing care during the induction, stabilization, and maintenance phases of MAT. Individual state Medicaid issues are too numerous and will not be specifically referred to on a state-by-state basis.